Prenetics Global Limited completed the sale of its 35 % equity interest in Insighta to Tencent on February 13 2026, a transaction announced on February 17 2026. The deal generated $70 million in cash consideration, of which $69 million was received immediately and $1 million was held in escrow.
The proceeds lifted Prenetics’ adjusted liquidity to $171.1 million as of February 15 2026. The liquidity pool now consists of $99.3 million in cash and cash equivalents, $29.3 million in financial assets at fair value through profit or loss, $7.3 million in escrow balances (including $6.3 million from ACT Genomics and $1 million from Tencent), and $35.2 million in Bitcoin holdings. The company remains debt‑free, reinforcing a strong balance‑sheet foundation.
Strategically, the sale marks the final milestone in Prenetics’ shift away from legacy diagnostics toward its high‑growth IM8 wellness brand. The $70 million infusion is earmarked to accelerate global expansion, fund product development, and support clinical trials for IM8, which has already achieved more than $100 million in annualized recurring revenue within 11 months and is sold in over 30 countries.
CEO Danny Yeung said the transaction “provides a significant injection of non‑dilutive capital, enhancing our ability to fully execute on IM8’s global growth strategy.” He added that the divestiture is the “final and most significant milestone” in the company’s strategic transformation.
Investors reacted favorably to the announcement, citing the substantial liquidity boost, the maintenance of a zero‑debt balance sheet, and the clear focus on the high‑growth IM8 brand as key drivers of confidence.
The sale follows a series of strategic moves: a January 2026 divestiture of the Europa business for up to $13 million, a voluntary warrant exchange program with 86.7 % participation, and a December 2025 decision to halt Bitcoin purchases and reallocate resources to IM8. The October 2024 investment by Tencent, which acquired a 15 % stake for $30 million and reduced Prenetics’ ownership from 50 % to 35 %, laid the groundwork for this final divestiture.
Prenetics will report its Q4 and full‑year 2025 results on February 18 2026, where analysts will assess the impact of the transaction on the company’s financial performance and growth trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.